Seres: FDA Clears IND for SER-155 Investigational Microbiome Therapeutic

 – SER-155 aims to prevent mortality in immunocompromised patients due to gastrointestinal infections, bacteremia and GvHD –

– In collaboration with Memorial Sloan Kettering Cancer Center, Seres will now advance SER-155 into a Phase 1b clinical study –

https://finance.yahoo.com/news/seres-therapeutics-announces-fda-clearance-120000118.html